Published in Medical Devices and Surgical Technology Week, November 23rd, 2008
"We found that CPT21 presented a broad anti-tumor spectrum against ten cancer cell lines in vitro, and the IC50 values ranged from 0.1 to 12.0 mc M. CPT21 was also capable to interrupt the DNA topoisemerase I activity and caused DNA double strand breaks during DNA replication. Proportion of apoptotic SGC7901 cells induced by CPT21 showed a time- and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.